Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Amortizatization of Intangibles for 6 consecutive years, with $10.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles rose 243.1% year-over-year to $10.8 million, compared with a TTM value of $10.8 million through Dec 2025, up 1853.69%, and an annual FY2025 reading of $10.8 million, up 1853.69% over the prior year.
  • Amortizatization of Intangibles was $10.8 million for Q4 2025 at Xeris Biopharma Holdings, up from -$7.6 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $10.8 million in Q4 2025 and bottomed at -$7.6 million in Q4 2024.
  • Average Amortizatization of Intangibles over 5 years is $746647.1, with a median of $382000.0 recorded in 2023.
  • The sharpest move saw Amortizatization of Intangibles skyrocketed 3813.7% in 2022, then tumbled 1296.69% in 2023.
  • Year by year, Amortizatization of Intangibles stood at -$60000.0 in 2021, then skyrocketed by 1056.67% to $574000.0 in 2022, then crashed by 1296.69% to -$6.9 million in 2023, then dropped by 10.31% to -$7.6 million in 2024, then soared by 243.1% to $10.8 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for XERS at $10.8 million in Q4 2025, -$7.6 million in Q4 2024, and $2.7 million in Q3 2024.